Big Pharma's Buying Spree Continues: Roche, GSK, and Novartis Strike Major Deals

　　【Pharmaceutical Network Industry Dynamics】Recently, several major cooperation and acquisition agreements in the global pharmaceutical industry have been successively finalized. These deals not only involve substantial amounts of capital but also focus on cutting-edge drug research and development areas, highlighting a clear trend in the global pharmaceutical industry to pursue growth through collaboration and breakthroughs via acquisitions, injecting strong momentum into innovative drug research and development.
 

On October 28, Chinese biopharmaceutical company Quanxin Biologics announced that it had entered into a global exclusive collaboration and licensing agreement with leading international pharmaceutical company Roche. Under the agreement, Roche will obtain global development, registration, manufacturing, and commercialization rights for Quanxin Biologics' self-developed long-acting autoimmune bispecific antibody QX031N. QX031N, a long-acting bispecific antibody targeting both TSLP (thymic stromal lymphopoietin) and IL-33 (interleukin 33), holds significant clinical potential in the field of autoimmune disease treatment.
 

In this collaboration, Roche will pay Quanxin Biotech an upfront payment of 750 million US dollars. If subsequent development, regulatory, and commercial milestones are achieved, Quanxin Biotech could receive milestone payments of up to 9.95 billion US dollars. Additionally, after the product is launched for commercial sales, Quanxin Biotech will also be entitled to tiered royalties based on global sales. This partnership not only provides Quanxin Biotech with substantial financial support but also leverages Roche's robust global R&D, manufacturing, and commercialization capabilities to accelerate the promotion of QX031N in the global market, allowing this innovative drug produced in China to potentially benefit more patients worldwide.
 

On the same day, another cross-border collaboration also garnered significant attention. GSK and Empirico announced a global exclusive licensing agreement for EMP-012. EMP-012 is a highly selective siRNA (small interfering ribonucleic acid) with a unique mechanism of action and strong potential, representing a cutting-edge product in the field of oligonucleotide drugs. According to the agreement, GSK will pay Empirico an upfront fee of $85 million. Additionally, as EMP-012 achieves success in development, regulatory, and commercial milestones, Empirico could receive up to $660 million in milestone payments, along with tiered royalties based on the product’s global net sales. GSK's move into the siRNA space marks a key step in its innovative drug development strategy, while Empirico leverages GSK’s resource advantages to advance the development of EMP-012. The collaboration allows both parties to complement each other’s strengths, jointly expanding the oligonucleotide drug market.
 

In addition to the cooperation agreement, on October 26, Swiss pharmaceutical giant Novartis announced a massive acquisition deal that shocked the industry. Novartis plans to acquire U.S.-based biopharmaceutical company Avidity Biosciences for approximately $12 billion. According to the acquisition terms, Avidity shareholders will receive $72 per share in cash, representing a 46% premium over the company’s closing price on October 24. Such a high premium fully reflects Novartis’ strong recognition of Avidity Biosciences’ core technology — the Antibody Oligonucleotide Conjugates (AOCs™) platform.
 

Antibody-Oligonucleotide Conjugate Technology as a Novel Drug Development Platform Combines the Targeting Ability of Antibodies with the Therapeutic Effects of Oligonucleotides, Showing Broad Prospects in Various Disease Treatment Fields. Through this acquisition, Novartis will gain access to multiple late-stage neuroscience projects under Avidity Biosciences, including candidates for Duchenne Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Myotonic Dystrophy Type 1. Once these candidates successfully reach the market, they will bring new therapeutic hope to patients with related rare diseases and further solidify Novartis' position in the fields of neuroscience and rare disease treatment.
 

In just a few days, the global pharmaceutical industry witnessed a flurry of high-value transactions, reflecting new trends in the sector's development. For instance, leading traditional pharmaceutical companies are shifting from "full-chain self-research" to "platform-based collaboration": Roche secured global rights to QX031N through licensing, both avoiding early-stage R&D risks and rapidly strengthening its autoimmune pipeline; GSK partnered with Empirico using a milestone payment model, reducing investment barriers through "upfront payment + performance-based royalties"; Novartis completed a full acquisition to directly control a technology platform, demonstrating an urgent demand for breakthrough technologies.
 

Moreover, the analysis pointed out that as the difficulty of drug research and development continues to increase and the cost of R&D keeps rising, both Chinese pharmaceutical companies and international leaders are more inclined to share risks and resources through cooperation, accelerating the R&D and commercialization process of innovative drugs. Additionally, innovative biotech companies with core technologies and potential drug candidates are becoming targets for acquisition by large pharmaceutical enterprises.
 

Looking ahead, innovative pharmaceutical companies focusing on niche technology tracks will continue to be the focal point for leading enterprises. Bispecific antibody drugs in the autoimmune field, siRNA technology in the gene therapy sector, and targeted delivery platforms in the rare disease domain—these promising technological directions will foster more cross-disciplinary collaborations. As China's innovative pharmaceutical industry develops, Chinese drug companies are expected to integrate into the global innovation network through technology exports, becoming key players in global pharmaceutical technology competition.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.